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INTRODUCTION
Metabolic syndrome (MetS) is a multiplex of clinical mani-
festations including hypertension, hyperglycemia, hypertri-
glyceridemia, diminished high-density lipoprotein choles-
terol (HDL-C), and abdominal obesity [1]. Non-alcoholic 
fatty liver disease (NAFLD) is widely considered the hepatic 
manifestation of MetS [2], and results from increased fat 
accumulation in the liver (steatosis). Pathological picture 
ranges from non-alcoholic fatty liver (NAFL), with absent 
hepatocyte injury or fibrosis, to the extreme construct of 
non-alcoholic steatohepatitis (NASH) in which hepatic ste-
atosis is associated with inflammation, liver cell injury and 
fibrosis [3]. NASH is a progressive disorder with up to 20% 
of patients develops cirrhosis within 10 years [4].
Insulin resistance and associated compensatory hyperin-
sulinemia are critical etiologic players in the development of 
MetS [5]. Insulin resistance inhibits glycogenesis and pro-
motes gluconeogenesis and free fatty acid (FFA) release from 
adipose tissue. The uptake of circulating FFA by hepato-
cytes is dysregulated, resulting in enhanced synthesis of tri-
glycerides and impaired FFA oxidation [6]. Liver injury in-
volves increased hepatocyte vulnerability to oxidative stress 
and ensuing lipid peroxidation. By-products of oxidative 
stress and lipid peroxidation are forceful chemoattractants 
of neutrophils with subsequent release of pro-inflammatory 
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cytokines such as tumor necrosis factor-α (TNF-α) which in 
turn exerts a positive feedback loop to increase insulin resis-
tance and neutrophils recruitment. Leptin and adiponectin 
are two cytokine-like mediators (adipokines) produced by 
adipose tissue. Leptin facilitates the secretion of TNF-α and 
other pro-inflammatory cytokines to increase insulin resis-
tance [7] while, on the flip side, adiponectin typically stim-
ulates fatty acid oxidation and augments insulin sensitivity 
[8]. 
Until recently, lifestyle modification has been the only 
treatment option for MetS. As of today, the FDA has not ap-
proved any medications to treat MetS; however, metformin 
(MET) and statins are logical candidates. A meta-analysis 
study published in 2007 demonstrated that monotherapy 
with MET leads to normalization of aminotransferases in 
significant fraction of patients more than dietary regime 
alone, and also improves steatosis on radiologic imaging [9]. 
Improvements in liver biochemistry and histology through 
treatment with statins have been also observed in some pa-
tients with NAFLD, although these studies were conducted 
on relatively small samples of patients [10]. To the best of 
our knowledge, the combination of MET with atorvastatin 
(ATR), a competitive inhibitor of HMG-CoA reductase of 
the statins family, for the treatment of MetS has not been in-
vestigated. The purpose of this study however is to study the 
potential of synergistic combination of MET and ATR in rat 
model of MetS. We reasoned that the documented improve-
ment of insulin resistance and glycemic control by MET, to-
gether with the established role of statins in the management 
of dyslipidemia may offer a broad spectrum therapeutic 




All experiments were conducted according to the local In-
stitutional Research Board guidelines and the Guide to the 
Care and Use of Laboratory Animals (8th edition, 2011, The 
National Academic Press, Washington, DC, USA). Seventy 
male Sprague-Dawley rats (9–weeks old, 160–190 g body wt) 
were acclimatized upon arrival for 5 days before experiments 
in naturally controlled lab of 22±2 °C and 12 h light–dark 
cycles. Fifty rats were pair-fed to high-carbohydrates, high-
fat diet (HCHF) while the remaining 20 rats fed on standard 
chow diet and served as negative control. The HCHF diet 
consisted of 395 g sweetened condensed milk, 200 g beef 
tallow, 175 g  fructose, 155 g powdered rat food, 25 g Hub-
ble, Mendel and Wakeman salt mixture, and 50 g water per 
kilogram of diet. In addition, the drinking water was sup-
plemented with 25% fructose. After 8 weeks, 10 rats from 
each group were euthanized to assess the progression of 
hepato-metabolic changes while the remaining 50 rats were 
allowed to continue for another 8 weeks to study the effect 
of drug treatments. 
Experimental design
After the initial 8 weeks of dietetic regime, rats were assigned 
into 5 groups (each of 10 rats) as follows – (1) negative control 
group – rats continued on standard chow diet without any 
drug treatment; (2) positive control group – rats continued 
on HCHF diet without any drug treatment; (3) MET group 
– rats continued on HCHF diet and receive MET 200 mg/
kg/day; (4) ATR group – rats continued on HCHF diet and 
receive ATR 30 mg/kg/day; and (5) ATR+MET group – rats 
continued on HCHF diet and receive ATR plus MET in the 
same previous doses. All drug treatments were commenced 
from the beginning of the 9th week to the end of 16th week. 
Drugs were given daily by oral gavage dissolved in 0.5 ml dis-
tilled water at 11:00 AM and all animals were observed daily 
for food and water intake while the body wt was measured 
weekly. At the end of 16th week, laparotomy was done under 
anesthesia following 12h period of food deprivation during 
which rats were given drinking water without fructose sup-
plementation. Livers were harvested and blood samples were 
collected from the heart and centrifuged at 1500 x g for 15 
min at 4°C to separate serum for biochemical analysis. 
Serum lipid profile
The total cholesterol (TC), triglycerides (TG) and high den-
sity lipoprotein cholesterol (HDL-C) were quantified by us-
ing colorimetric enzymatic assay kits (Crystal Chem Inc., 
The Netherland) according to the manufacturers’ instruc-
tions. The low density lipoprotein cholesterol (LDL-C) was 
calculated from Friedwald equation: LDL-C (mg/dl) = TC 
– (HDL-C + TG/5) [11].
Serological assays
Serum alanine transaminase (ALT) and aspartate transami-
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nase (AST) were measured by using ELISA kits (BioVision, 
USA). Serum insulin was analyzed by using rat insulin ELI-
SA kits (DRG International Inc., USA). TNF-α, leptin, and 
adiponectin in serum were measured by using ELISA kits 
(RayBiotech, Inc. USA) according to the manufacturers’ pro-
tocols.
Homeostasis model assessment of insulin 
resistance (HOMA-IR)
HOMA-IR was used to evaluate insulin resistance by the use 
of the insulin-glucose product assuming that young adult 
control rats have an average HOMA-IR analogous to HO-
MA-IR in humans [12]. The equation was as follows – HO-
MA-IR = fasting plasma insulin (μU/ml) x fasting plasma 
glucose (mmol/l)/22.5 [13].
Liver histopathology
Paraffin-embedded 4 μm liver sections were stained with 
hematoxylin & eosin (H&E) and examined by light micro-
scope. We used the activity score developed by the NASH 
Clinical Research Network to score the extent of steatosis, 
inflammation, and ballooning [14]. The overall score is cal-
culated as the sum of the scores for steatosis (0-3), lobular 
inflammation (0-3), and ballooning (0-2), and ranges from 0 
to 8 (Table 1). An overall score of ≤ 2 were diagnosed as nor-
mal morphology; a score of ≥ 5 is considered as a surrogate 
for the histological diagnosis of NASH while biopsies with 
scores between 2 and 5 were diagnosed as NAFL.
Statistical analysis
Statistical analyses were performed using the SPSS v22 (SPSS 
Inc., Chicago, USA). Data were presented as mean ± SD. 
Comparisons between means were performed as appropriate 
by using the Student’s t-test or one-way ANOVA followed by 
Tukey post hoc test. P-values of 0.05 or less were considered 
significant.
RESULTS
Hepato-metabolic characteristics after 8 
weeks of HCHF diet
Table 2 summarizes biological variables after 8 weeks of 
HCHF diet while Fig 1 illustrates changes in body wt during 
16 weeks of the study. After 8 weeks, rats fed on HCHF diet 
had marked increase in their body wt, serum glucose, insu-
lin, and HOMA-IR as compared with negative control rats 
(P<0.001 for all). There was also deterioration of serum 
lipid profile as observed with elevated TC, TG, and LDL-C 
(P<0.001 for all), and lowering of HDL-C (P<0.05) as com-
pared to control rats. Serum transaminases, leptin, and 
TNF-α were also higher in HCHF fed rats, while adiponec-
tin level was significantly lower than control rats (P<0.001 
for all). Histological examination of the livers of HCHF fed 
rats revealed mild macrovesicular steatosis, few inflamma-
tory cell infiltration and ballooning with an overall score of 
4.4±0.8 (Fig 6-B).
Table 1. Components of nonalcoholic fatty liver disease 
activity score [14].
Item Definition Score











< 2 foci per 200 × field
4-2 foci per 200 × field












Table 2. Biological and serological variables of rats fed on 
HCHF diet after 8 weeks.
Negative control HCHF diet
Body wt (g) 39.61 ± 198.5 54.90 ± 255.1†
Glucose (mmol/l) 0.88 ± 4.77 1.32 ± 6.82‡
Insulin (µU/ml) 1.65 ± 7.1 2.49 ± 11.03‡
HOMA-IR 0.19 ± 1.48 0.72 ± 3.34‡
TC (mg/dl) 37.43 ± 105.3 46.28 ± 198.2‡
TG (mg/dl) 20.48 ± 95.33 26.71 ± 120.17*
HDL-C (mg/dl) 17.64 ± 57.50 12.44 ± 39.31*
LDL-C (mg/dl) 14.54 ± 38.67 36.95 ± 134.0‡
ALT (U/l) 1.26 ± 5.5 4.61 ± 19.4‡
AST (U/l) 2.32 ± 9.8 5.63 ± 22.80‡
Leptin (pg/ml) 21.34 ± 77.50 47.67 ± 347.33‡
Adiponectin (ng/ml) 16.76 ± 64.0 4.35 ± 17.67‡
TNF-α (pg/ml) 0.87 ± 2.72 1.96 ± 6.53‡
Data are represented as mean ± SD of 10 rats.
Significance levels *P<0.05, †P<0.01, ‡P<0.001 vs. negative 
control (t-test).
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Effect of drug treatments after 16 weeks
At the end of the 16th week, rats treated with MET alone or in 
combination with ATR had significantly lower body weights 
as compared with non-treated HCHF fed rats (P<0.01) while 
those treated with ATR alone had non-significant reduction 
of their body weights (Fig 1). There was also significant at-
tenuation of serum insulin, glucose and HOMA-IR values 
by either of MET or ATR, however, improvements of these 
glycemic indices were less marked in rats treated with ATR 
than in rats treated with MET. On the flip side, the maximal 
improvement in glycemic indices was observed with com-
bined MET and ATR treatments (Fig 2). 
After 16 weeks, there was significant deterioration of se-
rum TC, TG, LDL-C and HDL-C in rats fed on HCHF diet 
(P<0.001 for all, Fig 3). Treatment with MET significantly 
lowered both serum TC and LDL-C (P<0.05) while treat-
ment with ATR significantly lowered serum levels of all the 
4 parameters with higher significance levels than those ob-
tained with MET treatment on TC and LDL-C. Rats treated 
with combined MET and ATR had the maximal improve-
ments in serum TC, TG, LDL-C and HDL-C compared to 
either MET or ATR alone (Fig 3).
Liver transaminases, AST and ALT, reflecting the degree 
of liver injury were significantly higher in HCHF fed rats 
than negative control rats (P<0.001, Fig 4). Rats treated with 
MET or ATR solely had significantly lower levels of hepatic 
enzymes as compared with non-treated rats. Co-treatment 
with MET and ATR significantly lowered the enzyme levels 
more than these obtained with either of drugs alone (Fig 4).
Fig 5 represents the effect of MET, ATR, and their combi-
nation on serum levels of TNF-α, leptin and adiponectin. 
After 16 weeks there was marked upsurge of serum TNF-α 
and leptin with reciprocal decrease of serum adiponectin 
in non-treated HCHF fed rats. MET treatment partially de-
creased TNF-α and leptin but not adiponectin, while ATR 
treatment partially restored TNF-α and adiponectin but not 
leptin. Rats received combined MET and ATR treatments 
had significant improvement of serum levels of the three cy-
tokines.
Fig 1. Body wt changes of control, non-treated HCHF fed rats and 
treated rats during 16 weeks duration of the study.
Fig 2. Effect of MET, ATR and their combination on the glycemic control in HCHF fed rats after 16 weeks (Significance levels: *P<0.05; † 
P<0.01; ‡ P<0.001 vs HCHF positive control rats – one way ANOVA of 10 rats).
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Fig 3. Effect of MET, ATR and their combination on serum lipid profile in HCHF fed rats after 16 weeks (Significance levels: *P<0.05; † 
P<0.01; ‡ P<0.001 vs HCHF positive control rats – one way ANOVA of 10 rats).
Fig 4. Effect of MET, ATR and their combination on serum AST and ALT in HCHF fed rats after 16 weeks (Significance levels: *P<0.05; † 
P<0.01 vs HCHF positive control rats – one way ANOVA of 10 rats).
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In comparison with normal liver tissue seen in rats fed on 
standard chow diet, livers of rats fed on HCHF diet for 16 
weeks showed progressive macrovesicular steatosis, inflam-
matory cell infiltration and ballooning with an overall score 
of 6.3±1.16 (Fig 6-C). Treatment of rats with either MET or 
ATR improved the histological deterioration as seen in re-
duced steatosis, inflammation, and ballooning with slightly 
better results seen with ATR over MET treatment (overall 
scores 3.7±0.51 and 4.2± 0.54 respectively, P<0.05, Fig 6-D 
and E). The combined MET and ATR treatment has signifi-
cantly attenuated the histological changes more than either of 
MET or ATR alone with an overall score of 3.2±0.5 (P<0.05 
and P<0.001 vs. ATR and MET respectively, Fig 6-F)..
DISCUSSION
MetS and commonly associated NAFLD is an area of ongoing 
medical research and a number of drugs are being investigat-
ed to find out safe and effective treatment. Although thera-
peutic benefit of MET and statins in MetS are documented 
in both experimental and clinical studies but information on 
the value of their combination in MetS/NAFLD is still lack-
ing. Our results presented herein clearly demonstrate good 
synergistic effect by MET and ATR in improving both hepa-
to-metabolic and morphological picture of the liver in rat 
replica of MetS. The benefit of using animal models of MetS 
in research is the ability to examine biochemical, function-
al, and histological changes which is difficult to conduct in 
humans. From the above finding, HCHF diet model used in 
this study correlates with other studies which reported that 
rat model of MetS shows most of pathogenic findings known 
to be responsible for the occurrence of MetS/NAFLD asso-
ciated with obesity and insulin resistance in humans [15]. 
The body of evidence accumulated during the past 20 
years has shown that the overall antihyperglycemic effect of 
MET is largely due to the inhibition of hepatic gluconeogen-
esis; however, a detailed explanation of MET mechanism of 
action in obesity, insulin resistance and MetS is still not fully 
understood. It seems plausible that part of MET pleotropic 
effects is due to increase in the AMP/ATP and ADP/ATP 
ratios [16] leading to stimulation of AMP kinase (AMPK), a 
primary cellular energy sensing enzyme [17]. However, this 
observation has been argued in experiments with hepato-
cytes deficient in either AMPK or its upstream activating 
cytosolic proteins [18]. The long-term favorable pleiotropic 
effects of MET may result not only from the AMPK-depen-
dent mechanism but also due to stimulation of other signal-
ing pathways such as increased nitric oxide (NO) synthesis 
consequent to activation of endothelial NO synthase (eNOS) 
[19], and suppression of oxidative stress through inhibition 
of mitochondrial electron transport chain [20].
As with our findings, there is a substantial body of evi-
dence that obesity-insulin resistance progression is positive-
ly correlated with an increase in pro-inflammatory cytokines 
such as TNF-α and leptin, and reduced plasma concentra-
tion of ‘protective’ adipokines, especially adiponectin [21-
Fig 5. Effect of MET, ATR and their combination on TNF-α, leptin, and adiponectin in HCHF fed rats after 16 weeks (Significance levels: 
*P<0.05; † P<0.01; ‡ P<0.001 vs HCHF positive control rats – one way ANOVA of 10 rats).
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22]. MET might be able to positively interfere with leptin 
and TNF-α production and partially recover adiponectin 
level and improve ‘adiponectin resistance’ present in obese 
individuals and patients with MetS. In human studies, MET 
treatment of obese adolescents with insulin resistance im-
proved inflammatory activity by eliciting a reduction in 
TNF-α concentration and preventing the decline in serum 
adiponectin concentration [23].
Although several studies have reported beneficial effects 
of statins in patients with MetS [24, 25], but clinicians are 
often concerned about prescribing statins for patients with 
elevated liver enzymes [26]. Surprisingly, we found that 
ATR has reduced aminotransferase levels in our rat mod-
el of MetS/NAFLD. Similar findings were also reported in 
patients with NAFLD in a number of studies [27-28] which 
provide our results more consolidation. As far as we know, 
very few studies have examined statins and MET combina-
tion in MetS [29]; moreover, most of these studies were fo-
cused mainly on the cardiovascular events, and even so, data 
obtained by these studies are inconsistent. More specifically, 
information on the effect of MET and ATR combination in 
patients with MetS and/or experimental models is lacking. 
Only, a one recent study in the allied field has shown that 
MET and ATR combination attenuated atherosclerosis in 
rabbits fed on high cholesterol diet [30].
 As expected in this study, improvement of the lipid pro-
file (TC, TG, LDL-C, and HDL-C) was marked in the ATR 
treated rats as opposed by the marked improvement of insu-
lin resistance (assessed by HOMA-IR) in the MET treated 
rats. In addition, after 8 weeks of intervention with either 
MET or ATR, a desirable decline of inflammatory markers, 
particularly TNF-α, was noted. We also observed that while 
the effects of the two drugs were differential on leptin and 
adiponectin concentrations, but the combined treatments 
triggered greater outcome in the reduction of TNF-α and 
leptin on one hand, and recovery of serum adiponectin on 
the other hand. These serological findings have been further 
confirmed by morphological assessment of liver sections 
where we found that HCHF fed rats treated with MET and 
ATR solely has improved the overall histological score as ev-
idenced by decreased steatosis, inflammation, and balloon-
ing with somewhat slightly favorable result with ATR than 
MET. This finding seems reasonable since the major ATR 
mechanism of action is directed toward reduction of choles-
terol biosynthesis and modulation of lipid metabolism [31], 
consequently reduction of hepatic steatosis. Similar results 
Fig 6. H&E stained liver sections from control and treated rats. Normal morphology as seen in control rats after 16 weeks (A). Mild 
macrovesicular steatosis with few inflammatory cell infiltration and ballooning seen in HCHF fed rats after 8 weeks (B). Progressive steatosis 
with marked inflammatory cell infiltration seen in HCHF fed rats after 16 weeks (C). Reduced histological changes in MET and ATR treated 
rats (D and E respectively). Maximal improvement was seen in rats treated with MET and ATR combination (F). (X100).
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were also obtained in some previous studies [27-28]. A more 
important finding presented herein is that co-treatment with 
MET and ATR could efficiently ameliorate histological de-
terioration seen in HCHF fed rats more significantly than 
monotherapy with either MET or ATR alone. This finding 
was supported by biochemical and serological data of the 
present study.
A major limitation of this study is that we did not in-
vestigate effects related to the cardiovascular complications 
of MetS such as blood pressure, myocardial functions or 
vascular abnormalities as we aimed mainly at studying the 
hepato-metabolic function. Another limitation is that we did 
not investigate the effect of drug combination at the molec-
ular levels. Despite these limitations, we think that this study 
might provide useful information on the beneficial outcome 
of MET and ATR in experimental MetS which could be eas-
ily reproduced in the clinical setting on patients with MetS 
since MET is commonly used for long-term by patients with 
obesity, and type-2 diabetes with significant margin of safe-
ty; likewise, ATR is given for long-term control of dyslipid-
emia with good tolerability by most patients. Larger clinical 
studies would be indeed more useful to consider limitations 
of data at hand and to consolidate the value of this drug com-
bination in the management of patients with MetS.
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